Back to top

Curis, Inc. (CRIS)

(Real Time Quote from BATS)

$0.82 USD


-0.02 (-2.36%)

Updated Dec 17, 2018 12:32 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
Strong Buy
Strong Sell

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Company Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

General Information

Curis, Inc.



Phone: 617-503-6500

Fax: 617-503-6501



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 9/30/2018
Next EPS Date 3/14/2019

EPS Information

Current Quarter EPS Consensus Estimate -0.23
Current Year EPS Consensus Estimate -1.03
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 3/14/2019

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 0.84
52 Week High 5.20
52 Week Low 0.60
Beta 1.14
20 Day Moving Average 518,782.91
Target Price Consensus 11.50


% Price Change
4 Week -42.08
12 Week -48.15
YTD -76.00
% Price Change Relative to S&P 500
4 Week -39.17
12 Week -41.56
YTD -76.94
Share Information
Shares Outstanding (millions) 33.11
Market Capitalization (millions) 27.81
Short Ratio NA
Last Split Date 5/30/2018
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 60.00%
vs. Previous Quarter 15.38%
Sales Growth
vs. Previous Year 16.49%
vs. Previous Quarter 20.74%
Price Ratios
Price/Book 35.66
Price/Cash Flow NA
Price / Sales 2.54
9/30/18 -299.20
6/30/18 -225.77
3/31/18 -247.46
9/30/18 -59.60
6/30/18 -63.38
3/31/18 -68.71
Current Ratio
9/30/18 2.63
6/30/18 3.01
3/31/18 3.60
Quick Ratio
9/30/18 2.63
6/30/18 3.01
3/31/18 3.60
Operating Margin
9/30/18 -316.98
6/30/18 -407.29
3/31/18 -472.13
Net Margin
9/30/18 -316.98
6/30/18 -407.29
3/31/18 -472.13
Pre-Tax Margin
9/30/18 -316.87
6/30/18 -407.14
3/31/18 -472.01
Book Value
9/30/18 0.02
6/30/18 0.21
3/31/18 0.44
Inventory Turnover
9/30/18 NA
6/30/18 NA
3/31/18 NA
9/30/18 38.74
6/30/18 4.43
3/31/18 2.24
Debt to Capital
9/30/18 97.48
6/30/18 81.60
3/31/18 69.18